1. Scrip
  2. >>Business

Biogen Partners With InnoCare To Keep Up With BTK Inhibitor Leaders in MS

$125m Upfront For InnoCare

 
• By Andrew McConaghie and Brian Yang

BTK Inhibitors could be a major advance multiple sclerosis therapy, and Biogen has bought into a potential challenger to Phase III frontrunner from Sanofi and Roche.

Biogen
Biogen wants to stay competitive in MS, and sees BTK inhibitors a potentially key to the field's future. • Source: Alamy

Biogen has paid $125m upfront to get its hands on Chinese company InnoCare’s orelabrutinib, one of a number of promising BTK inhibitors which could transform multiple sclerosis (MS) treatment.

While Biogen is in the news for the ongoing controversy around its newly approved Alzheimer’s drug Aduhelm (aducanumab), it is also looking to defend its presence in MS, its biggest franchise, where revenues from its blockbuster

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

More from Scrip

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.